SCHEMBL30989787

SCHEMBL30989787

CN(Cc1cccc(C#N)c1)S(=O)(=O)c1cc(F)cnc1OC(F)F

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GRIN1 Q05586 2/20 0.37
▸ GRIN2B Q13224 2/20 0.37
▸ VNN1 O95497 2/20 0.36
▸ SLC22A12 Q96S37 3/20 0.35
▸ ALDH1A1 P00352 2/20 0.35
▸ HPGD P15428 1/20 0.35
▸ SLC6A2 P23975 1/20 0.35
▸ SLC6A4 P31645 1/20 0.35
▸ SLC6A3 Q01959 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ DPP4 P27487 1/20 0.35
▸ DPP9 Q86TI2 1/20 0.35
▸ DPP7 Q9UHL4 1/20 0.35
▸ NR3C1 P04150 1/20 0.34
▸ NAMPT P43490 1/20 0.34
▸ GLA P06280 1/20 0.34
▸ MEP1A Q16819 1/20 0.34
▸ MEP1B Q16820 1/20 0.34
▸ MAOB P27338 1/20 0.34
▸ FNTA P49354 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30989797 0.88 MAOA (0.43) ALDH1A1HPGDNAMPTMAOB
SCHEMBL30989816 0.85 L3MBTL1 (0.39) ALDH1A1HPGDMAPTNAMPTMAOB
SCHEMBL30989847 0.81 BMP1 (0.33) ALDH1A1HPGDNAMPTMAOB
SCHEMBL30989819 0.79 NAMPT (0.41) GRIN1ALDH1A1HPGDNAMPTMAOB
SCHEMBL30989763 0.78 RIPK1 (0.36) ALDH1A1HPGDMAOB
SCHEMBL30989789 0.76 KDM4E (0.40) ALDH1A1HPGDMAPTNAMPT
SCHEMBL30989770 0.72 TRPV4 (0.36) SLC6A4
SCHEMBL30989752 0.72 TRPV4 (0.36) SLC6A4
SCHEMBL30989865 0.70 PTGER4 (0.41) GRIN1GRIN2BVNN1MEP1AMEP1B
SCHEMBL30989845 0.65 TRPV4 (0.56) SLC22A12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4612131-A1 NICOTINAMIDE DERIVATIVES FOR USE IN TREATING DISORDERS ASSOCIATED WITH KCNK13 ACTIVITY Cerevance, Inc. (US) 2025-09-10 — — EP claimed
WO-2024095003-A1 NICOTINAMIDE DERIVATIVES FOR USE IN TREATING DISORDERS ASSOCIATED WITH KCNK13 ACTIVITY Cerevance, Inc. (US) 2024-05-10 — — WO claimed
EP-4612131-A1 NICOTINAMIDE DERIVATIVES FOR USE IN TREATING DISORDERS ASSOCIATED WITH KCNK13 ACTIVITY Cerevance, Inc. (US) 2025-09-10 — — EP disclosed
WO-2024095003-A1 NICOTINAMIDE DERIVATIVES FOR USE IN TREATING DISORDERS ASSOCIATED WITH KCNK13 ACTIVITY Cerevance, Inc. (US) 2024-05-10 — — WO disclosed
Send feedback